![Photo](/media/story/2347/thumbnail.jpg)
Novartis launched once-a-year osteoporosis treatment
The Swiss company Novartis recently received the FDA approval for the U.S. market for their new osteoporosis drug “Reclast”, a therapy that is only given once a year via a 15-minute infusion. The new treatment option is especially designed for women who suffer from post-menopausal osteoporosis.